![]() |
Name |
N-acetyl-β-oxotryptamine
|
Molecular Formula | C12H12N2O2 | |
IUPAC Name* |
N-[2-(1H-indol-3-yl)-2-oxoethyl]acetamide
|
|
SMILES |
CC(=O)NCC(=O)c1c[nH]c2ccccc12
|
|
InChI |
InChI=1S/C12H12N2O2/c1-8(15)13-7-12(16)10-6-14-11-5-3-2-4-9(10)11/h2-6,14H,7H2,1H3,(H,13,15)
|
|
InChIKey |
QYDMJTFKQVPEHJ-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 216.24 | ALogp: | 1.5 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 62.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.771 |
Caco-2 Permeability: | -4.753 | MDCK Permeability: | 0.00000968 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.277 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.959 |
Blood-Brain-Barrier Penetration (BBB): | 0.916 | Plasma Protein Binding (PPB): | 27.17% |
Volume Distribution (VD): | 1.498 | Fu: | 72.49% |
CYP1A2-inhibitor: | 0.798 | CYP1A2-substrate: | 0.292 |
CYP2C19-inhibitor: | 0.244 | CYP2C19-substrate: | 0.09 |
CYP2C9-inhibitor: | 0.05 | CYP2C9-substrate: | 0.594 |
CYP2D6-inhibitor: | 0.033 | CYP2D6-substrate: | 0.486 |
CYP3A4-inhibitor: | 0.137 | CYP3A4-substrate: | 0.12 |
Clearance (CL): | 3.868 | Half-life (T1/2): | 0.873 |
hERG Blockers: | 0.04 | Human Hepatotoxicity (H-HT): | 0.185 |
Drug-inuced Liver Injury (DILI): | 0.436 | AMES Toxicity: | 0.455 |
Rat Oral Acute Toxicity: | 0.343 | Maximum Recommended Daily Dose: | 0.293 |
Skin Sensitization: | 0.375 | Carcinogencity: | 0.077 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.034 |
Respiratory Toxicity: | 0.584 |